ANUPAMA GOWDA
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology ATLANTA, GA NPI 1508947870
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology GA Retrophin, Inc. All categories
General Payments — all program years on this page
$1,864.61
- Category: General Payments
- Program years: PY2018–2024
- Record count: 70
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $226.55 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $226.55 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Retrophin, Inc. | $106.89 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $42.71 | 2 |
| Relypsa, Inc. | $27.26 | 1 |
| Acerta Pharma LLC | $19.96 | 1 |
| Fresenius USA Marketing, Inc. | $16.20 | 1 |
| Amgen Inc. | $13.53 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1086937419 | Novartis Pharmaceuticals Corporation | $16.87 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086937421 | Novartis Pharmaceuticals Corporation | $25.84 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1105851806 | AstraZeneca Pharmaceuticals LP | $19.96 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1111587744 | Amgen Inc. | $13.53 | 12/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1124049590 | Vifor Pharma, Inc. | $27.26 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1149879191 | Travere Therapeutics, Inc. | $16.17 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1149879195 | Travere Therapeutics, Inc. | $90.72 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1154193670 | Fresenius USA Marketing, Inc. | $16.20 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.